ExeGi Pharma, LLC announced the launch of the new probiotic formulation, Visbiome™ and Visbiome™ Extra Strength. Visbiome contains the pioneering probiotic blend developed by Professor Claudio De Simone, M.D., Ph.D. (the "De Simone Formulation"), and it has the same strains, in the same concentrations and proportions, and is therapeutically equivalent to the VSL#3®1 probiotic blend produced before January 31, 2016. Visbiome, a medical food, delivers anti-inflammatory probiotic bacteria in high concentrations, normalizing the gut flora and providing sustained relief from symptoms of multiple gastroenterological conditions including ulcerative colitis, chronic pouchitis and irritable bowel syndrome (IBS).


Everyone likes to talk about innovation, but how can you stop simply talking about and start driving real innovation in biotech? We looked at some of the most ground-breaking, silo-busting movers and shakers around to bring you the "Top 5 Ways to Innovate in Biote


Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that Christine Brennan, PhD, Principal at Novartis Venture Fund, has joined its Board of Directors effective immediately. Dr. Brennan replaces Florent Gros from Novartis Venture Fund.

“We are extremely pleased to welcome Dr. Brennan to our Board. She has an impressive background in the biopharmaceutical industry, and her experience and guidance will be invaluable as we continue to advance the clinical development of our three drug candidates,” said Bill Enright, President and Chief Executive Officer of Altimmune. “We would also like to thank Mr. Gros for his service to Altimmune over the past year.”


GlaxoSmithKline plc (LSE/NYSE: GSK) today announces a series of agreements with Aspen (JSE: APN) aligned with GSK’s strategy of simplification through focusing on core therapeutic areas.

GSK will divest its anaesthesia portfolio to Aspen for £180 million plus milestones of up to £100 million. In addition to this divestment, GSK and Aspen have entered into parallel agreements to terminate their collaboration in Sub-Saharan Africa and for Aspen to exercise its option to acquire GSK’s remaining thrombosis business in certain retained markets.

Digital health technology leader WellDoc announced today it has entered a commercial partnership agreement with LifeScan Inc., one of the Johnson & Johnson Diabetes Care Companies (JJDCC) and a world leader in blood glucose monitoring, to deliver across the United States a best-in-class digital health solution for Type 2 diabetes. The companies will integrate WellDoc’s clinically validated BlueStar® diabetes management platform and mobile application, which is the first digital therapeutic approved by the U.S. Food and Drug Administration for adults who live with Type 2 diabetes, with LifeScan’s OneTouch Verio Flex™ blood glucose monitoring system with built-in Bluetooth® Smart Technology and the OneTouch Reveal digital system. The combined offering will seek to create a comprehensive, data-driven and payer-reimbursed program for Type 2 diabetes management.


Tech star and billionaire Steve Case has been hammering home one idea for the last few years — that the future of tech and startups rests outside of the traditional Silicon Valley ecosystem and in the fertile plains of America’s heartland.

Now, with less than a month until his fifth “Rise of the Rest” tour, he sees that idea gaining traction.


Recently there have been numerous articles and editorials understandably scrutinizing the increases in pricing of EpiPen produced by Mylan, a generic drug company. The strong reaction to the behavior of Mylan and a few other companies is threatening to impede the ability of R&D-focused innovator companies to provide innovative, life-changing new therapies to patients.


The University of Maryland School of Medicine tested out its first Zika vaccine shots Tuesday, in hopes to further research that could lead to a vaccine used around the world.

The vaccine was developed by the National Institute of Health, which chose three places to test, first in their labs in Bethesda, then at the U of M School of Medicine, and finally at Emery University in Atlanta.


Verily, Alphabet's life sciences group, is investing big in developing technologies for the millions of people worldwide with diabetes.

Verily announced today that it is teaming up with pharmaceutical giant Sanofi to fund and spin out a new venture, Cambridge, Mass.-based Onduo, which is focused on helping clinicians and their patients manage the disease. The companies have tapped a new CEO to lead the startup, trained emergency-medicine physician Joshua Riff, from United Healthcare-owned Optum.


At first glance, Moderna Therapeutics looks like the most enviable biotech startup in the world. It has smashed fundraising records and teamed up with pharmaceutical giants as it pursues a radical plan to revolutionize medicine by transforming human cells into drug factories.

But the reality is more complicated.


Tekes – the Finnish Funding Agency for Innovation (Tekes) and IBM (NYSE: IBM) today announced a partnership that will enable Finland to utilize Watson cognitive computing to help doctors improve the health of its citizens, and strengthen and develop the Finnish innovation and business ecosystem in the fields of health and well-being. To facilitate the collaboration, IBM intends to establish a Watson Health Center of Excellence in Finland, the first Nordic Healthcare Competence Center, and the first National Imaging Center of Excellence outside the United States in Finland. These centers are expected to employ 150 people over the next few years.


IDT Biologika, a globally integrated manufacturer of vaccines and biopharmaceuticals, announces today the one-year anniversary celebration of its first U.S. contract manufacturing facility in Rockville, Maryland. The state-of-the-art facility offers custom, end-to-end solutions to support the manufacture of viral and microbial vaccines (live and attenuated), gene and cancer therapies, and therapeutic proteins. IDT commemorates its first anniversary with a special program and tours of its facility for local political leaders and members of the biopharmaceutical industry.

The 2016 Steering Committee of the Montgomery County Executive Hispanic Gala (MCEHG) announces that Montgomery County Public Schools Assistant Principal Vilma C. Nájera will be the recipient of the "Educator of the Year" Award to be presented during the gala celebration on September 22, 2016 at The Fillmore Silver Spring.

Ms. Vilma C. Nájera is an Assistant Principal at Springbrook High School and one of the county coordinators for the Minority Scholars Program. Through her work last year at Springbrook, there was an increase in the number of Hispanic males graduating. She also launched the Minority Scholars Program at Springbrook.

The Minority Scholars Program, MSP, is a group of student leaders that focuses on closing the achievement gap at their schools and county wide.


From Mark Suster:

"I recently read a blog post by Beezer Clarkson, Managing Director of Sapphire Ventures about why entrepreneurs should care about from whom their VC funds raise their capital. I spent a bunch of time thinking about this position — especially since Beezer is an investor in Upfront Ventures. There are a lot of things I think entrepreneurs should care about when raising from a VC:"


Alexandria Real Estate (NYSE:ARE) is about as successful a Wall Street story as you'll find. Started in 1994 as what management fondly recalls as a garage startup, the company now is one of the most successful and unique REITs on the market today. What makes the company so special is that Alexandria was the first REIT to focus exclusively on life science and biotechnology clients, specifically in the most prime real estate markets: Boston, San Francisco, New York City, etc.


California Life Sciences Institute (CLSI) today announced the appointment of Heather Shane to build and lead the CLSI CARB-X accelerator, which will provide non-dilutive funding, business support and subject matter expertise to companies with innovative antibiotic product candidates. The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is the world’s largest public-private partnership focused on tackling one of the greatest modern threats to public health — antibiotic resistance. CARB-X will commit $50 million during the first year, and at least $350 million over five years, toward preclinical research and development with the aim of accelerating antibiotic product development over the next 25 years. CLSI is the non-profit partner of the California Life Sciences Association (CLSA), and supports the foundations of innovation – workforce development, STEM education and entrepreneurship – that have made California home to the world’s most prominent life sciences ecosystem.


The next CONNECTpreneur event is September 28 at the Hyatt Regency Bethesda.  More info at connectpreneur.org

There’s a 40% discount code just for eBiz Alert subscribers:  Enter CODE:  MOCO when you register at http://connectpreneursept2016.eventbrite.com.

This event’s Fireside guest is Seth Goldman, Founder and TeaEO, Honest Tea.

There will be a terrific VC panel including Moderator: Eric Koefoot, Co-Founder and Managing Partner, Public Relay, CEO and Publisher, US News Ventures, Founder and CEO, Five Star Alliance; AJ Jaghori, CEO Solebrity; Founder HelloLoCo; Beth Johnson, Founder and CEO, RP3 Agency; Jeannette Lee, Founder and CEO, Cyper; Founder and CEO, SYTEL.


Two Maryland-based companies are racing to get a vaccine for respiratory syncytial virus (RSV) to market--and one just picked up a regulatory boost.

MedImmune, AstraZeneca's ($AZN) biologics research and development arm, announced on Thursday that the FDA is fast-tracking its RSV vaccine, MEDI8897. It joins Novavax ($NVAX), which received FDA fast-track designation for its candidate in November.


Helping patients means transparency and clarity

Every day, thousands of Americans hear the dreaded “c word” from their doctor. I know the fear and the numbness that sets in with the cancer of a loved one.

What happens next can make the difference between life and death. If there’s a treatment that can help, there’s hope. But for some people, hope is a clinical trial that will ultimately determine whether a new therapy can slow or stop their cancer.


You and your company team will be competing against other biotech companies to win the coveted BioBowl Trophy and bragging rights! Come out, Team Build and Network with some friendly competition!

Date: Thursday, October 13, 2016 Time: 4:00 - 6:30 PM (TBC) Location: Bowlmor – 15720 Shady Grove Rd, Gaithersburg MD 20877

For more info, please contact Sarah Meisheid at This email address is being protected from spambots. You need JavaScript enabled to view it. or 301-398-2431


A Pasadena-based real estate company that has grown into a world-class developer for science and technology campuses is expanding its reach into the life science industry.

Alexandria Real Estate equities — an urban office real estate investment trust that was founded in 1994 — has put up buildings in virtually every major city where life sciences are studied in the United States, according to Xconomy.